Bastide Le Confort Medical (LTS:0IP1) 5-Year EBITDA Growth Rate: 4.10% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0IP1 Bastide Le Confort Medical SA LTS:0IP1
70 GF Score
Price €22.60
GF Value €26.01
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Bastide Le Confort Medical 5-Year EBITDA Growth Rate?

Bastide Le Confort Medical LTS:0IP1 -1.09% 70 5-Year EBITDA Growth Rate is 4.10% as of Dec. 2025. GuruFocus rates LTS:0IP1 with a GF Score™ of 70/100 and a GF Value™ of €26.01 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Bastide Le Confort Medical's EBITDA per Share for the six months ended in Dec. 2025 was €6.71.

During the past 12 months, Bastide Le Confort Medical's average EBITDA Per Share Growth Rate was 14.30% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 1.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 4.10% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 13.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Bastide Le Confort Medical was 28.20% per year. The lowest was -1.90% per year. And the median was 14.00% per year.


Bastide Le Confort Medical  (LTS:0IP1) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.


Bastide Le Confort Medical 5-Year EBITDA Growth Rate Related Terms


LTS:0IP1 vs MCK, COR, CAH: 5-Year EBITDA Growth Rate Comparison

For the Medical Distribution subindustry, Bastide Le Confort Medical's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bastide Le Confort Medical 5-Year EBITDA Growth Rate vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Bastide Le Confort Medical's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Bastide Le Confort Medical's 5-Year EBITDA Growth Rate falls into.


LTS:0IP1
70GF Score
Bastide Le Confort Medical SA LTS:0IP1
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bastide Le Confort Medical 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 4.10% mean?
Bastide Le Confort Medical (LTS:0IP1) has a 5-Year EBITDA Growth Rate of 4.10% as of Dec. 2025. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Bastide Le Confort Medical and its competitors.
Is Bastide Le Confort Medical's 5-Year EBITDA Growth Rate too high?
Bastide Le Confort Medical's current 5-Year EBITDA Growth Rate is 4.10%. Overall, Bastide Le Confort Medical has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bastide Le Confort Medical's 5-Year EBITDA Growth Rate compare to MCK and COR?
Bastide Le Confort Medical's 5-Year EBITDA Growth Rate of 4.10% can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Distribution company?
A good 5-Year EBITDA Growth Rate depends on the Medical Distribution industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Bastide Le Confort Medical and its competitors. Bastide Le Confort Medical's current 5-Year EBITDA Growth Rate is 4.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bastide Le Confort Medical stock overvalued right now?
Based on GuruFocus' analysis, Bastide Le Confort Medical (LTS:0IP1) is currently considered Modestly Undervalued. The stock's GF Value™ is €26.01, compared to a current price of €22.60 — trading 13.1% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 4.10%. Bastide Le Confort Medical's overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Bastide Le Confort Medical (LTS:0IP1), the current 5-Year EBITDA Growth Rate is 4.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bastide Le Confort Medical (LTS:0IP1) Overvalued in 2026?

Based on GuruFocus' analysis, Bastide Le Confort Medical stock appears to be undervalued. The current stock price of €22.60 is trading 13.1% below its estimated GF Value™ of €26.01. GuruFocus considers Bastide Le Confort Medical to be Modestly Undervalued.

Key valuation signals for LTS:0IP1:

  • 5-Year EBITDA Growth Rate: 4.10%
  • GF Value™: €26.01 vs. price of €22.60 (13.1% below fair value)
  • GF Score™: 70/100 with 2 warning signs

No single metric tells the full story. See the LTS:0IP1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bastide Le Confort Medical Business Description

Other Exchanges BLC:France1DJ:Germany
Address 12, Avenue de la Dame, Caissargues, FRA, 30132
Bastide Le Confort Medical SA is a France-based company that is engaged in the sale and rental of medical supplies and equipment for the home care of the elderly, sick and disabled. The company provides care equipment, such as hospital beds, personal assistance products, nutrition, insulin pumps, and syringe-drivers.
70GF Score

Get the complete analysis for LTS:0IP1

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€22.60
Price
€26.01
GF Value